The USMCA includes provisions for Canadian IP that extend protection for biologics and copyright, exporting what some observers see as the worst of US IP law to its northern neighbour. Ellie Mertens reports
J Bradley White and Nathaniel Lipkus of Osler analyse the changes introduced by the amendments to the PMNOC Regulations, examining the rules around the 24-month timeline for actions, appropriate parties in a proceeding, NOAs, early patent dismissals, confidentiality and the 24-month stay
Steve Garland and Jean-Sébastien Dupont of Smart & Biggar consider five reasons why carrying out patent litigation in Canada is preferable to US proceedings, including no opportunity for forum shopping, no jury trials and no inter partes reviews
November / December 2018
The 50 most influential people in IP
Managing IP reveals our pick of the people driving intellectual property law, policy and business this year. Read the full list here
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2018 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International